Viewing nowDementia Tablets (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Korea Union Pharm (Co., Ltd.)

MFDS item code 200501472 · Notified 2005.04.18 · Insurance code 665500570
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only when a caregiver is able to periodically check that the patient is taking the medication. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be periodically reassessed. This medicine may be taken with or without food. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1-7): Administer 5mg daily for 7 days. Week 2 (Days 8-14): Administer 10mg daily (5mg twice daily) for 7 days. Week 3 (Days 15-21): Administer 15mg daily (10mg in the morning and 5mg in the evening) for 7 days. From Week 4: Administer 20mg daily (10mg twice daily). Maintenance dose: The recommended maintenance dose is 20mg daily (10mg twice daily). Elderly: Based on clinical data, the recommended dose for elderly patients aged 65 years and older is 20mg daily (10mg twice daily). Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg daily according to the standard dose-escalation regimen after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), the daily dose should be reduced to 10mg. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medication should not be administered to certain patients. First, individuals allergic to any of the components of this medication should not take it. Second, patients with severely impaired liver function or severely diminished kidney function should not use this medication. Third, individuals with lactose intolerance or specific genetic metabolic disorders should also not use this medication. Furthermore, special caution is needed for patients with a history of seizures or those prone to seizures, those taking other medications with similar actions, those expected to have changes in urine acidity, and patients with heart disease or uncontrolled hypertension. Taking this medication may cause side effects such as dizziness, headache, constipation, drowsiness, and hypertension, and in rare cases, symptoms like confusion, hallucinations, and seizures may also occur. When used with other medications, interactions may occur, so caution is especially required when combining it with NMDA antagonists, antipsychotic medications, skeletal muscle relaxants, and anticoagulants. Women who are pregnant or breastfeeding must consult a doctor before taking this medication, and pregnant women must decide cautiously as it may affect the fetus. Safety and efficacy regarding children under the age of 18 have not been sufficiently confirmed. In cases of overdose, severe symptoms such as coma, hallucinations, and seizures may occur, so immediate medical attention is required if this medication is overdosed. This medication is primarily used for patients with severe Alzheimer's disease, who generally have reduced capabilities for driving or operating machinery, so special care is needed during these activities. Finally, this medication should be kept out of reach of children, and transferring it to other containers should be avoided to maintain quality and safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air and moisture, and it is best to store it at room temperature between 1 degree and 30 degrees Celsius. Storing it this way helps to maintain the medication's effectiveness and prevents deterioration.
White oval film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Korea Union Pharm (Co., Ltd.)
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.